Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibentatug - ZielBio

Next Previous
Drug Profile

Ibentatug - ZielBio

Alternative Names: ZB-131

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZielBio
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cholangiocarcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Jun 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) (IV) , prior to June 2023 (ZielBio pipeline, June 2023)
  • 02 Jun 2023 Safety, pharmacokinetics and efficacy data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 14 Apr 2023 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical trial in pancreatic cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top